FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) Stock Fundamental Analysis
USA - NASDAQ:FBIOP - US34960Q2084
6.8 USD
+0.1 (+1.49%)
Overall FBIOP gets a fundamental rating of 2 out of 10. We evaluated FBIOP against 531 industry peers in the Biotechnology industry. Both the profitability and financial health of FBIOP have multiple concerns. FBIOP is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year FBIOP has reported negative net income.
FBIOP had a negative operating cash flow in the past year.
FBIOP had negative earnings in each of the past 5 years.
In the past 5 years FBIOP always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -15.04%, FBIOP belongs to the top of the industry, outperforming 80.60% of the companies in the same industry.
FBIOP has a better Return On Equity (-54.76%) than 63.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.04% | ||
| ROE | -54.76% | ||
| ROIC | N/A |
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 70.91%, FBIOP belongs to the top of the industry, outperforming 81.54% of the companies in the same industry.
FBIOP's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for FBIOP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.91% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
2. Health
2.1 Basic Checks
FBIOP does not have a ROIC to compare to the WACC, probably because it is not profitable.
FBIOP has more shares outstanding than it did 1 year ago.
The number of shares outstanding for FBIOP has been increased compared to 5 years ago.
The debt/assets ratio for FBIOP is higher compared to a year ago.
2.2 Solvency
FBIOP has an Altman-Z score of -6.88. This is a bad value and indicates that FBIOP is not financially healthy and even has some risk of bankruptcy.
FBIOP has a Altman-Z score of -6.88. This is in the lower half of the industry: FBIOP underperforms 66.67% of its industry peers.
FBIOP has a Debt/Equity ratio of 1.14. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.14, FBIOP is doing worse than 77.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.88 |
ROIC/WACCN/A
WACC9.47%
2.3 Liquidity
FBIOP has a Current Ratio of 1.92. This is a normal value and indicates that FBIOP is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.92, FBIOP is doing worse than 77.02% of the companies in the same industry.
A Quick Ratio of 1.70 indicates that FBIOP should not have too much problems paying its short term obligations.
FBIOP has a Quick ratio of 1.70. This is in the lower half of the industry: FBIOP underperforms 79.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.7 |
3. Growth
3.1 Past
FBIOP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.44%, which is quite impressive.
The Revenue for FBIOP has decreased by -28.23% in the past year. This is quite bad
FBIOP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.50% yearly.
EPS 1Y (TTM)37.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.51%
Revenue 1Y (TTM)-28.23%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%10.18%
3.2 Future
The Earnings Per Share is expected to grow by 11.48% on average over the next years. This is quite good.
Based on estimates for the next years, FBIOP will show a very strong growth in Revenue. The Revenue will grow by 64.44% on average per year.
EPS Next Y69.12%
EPS Next 2Y18.7%
EPS Next 3Y11.48%
EPS Next 5YN/A
Revenue Next Year26.68%
Revenue Next 2Y35.26%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FBIOP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FBIOP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.7%
EPS Next 3Y11.48%
5. Dividend
5.1 Amount
No dividends for FBIOP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP
NASDAQ:FBIOP (11/12/2025, 8:18:13 PM)
6.8
+0.1 (+1.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners16.67%
Inst Owner ChangeN/A
Ins Owners14.9%
Ins Owner ChangeN/A
Market Cap202.30M
Revenue(TTM)59.30M
Net Income(TTM)-24.05M
Analysts82.5
Price Target29.24 (330%)
Short Float %0%
Short Ratio0.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.22
Dividend Growth(5Y)-17.74%
DP-2.8%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.62%
Min EPS beat(2)-36.17%
Max EPS beat(2)4.93%
EPS beat(4)2
Avg EPS beat(4)-13.52%
Min EPS beat(4)-36.17%
Max EPS beat(4)4.93%
EPS beat(8)6
Avg EPS beat(8)17.06%
EPS beat(12)7
Avg EPS beat(12)9.15%
EPS beat(16)8
Avg EPS beat(16)-15.31%
Revenue beat(2)2
Avg Revenue beat(2)10.78%
Min Revenue beat(2)10.71%
Max Revenue beat(2)10.85%
Revenue beat(4)2
Avg Revenue beat(4)-10.74%
Min Revenue beat(4)-55.48%
Max Revenue beat(4)10.85%
Revenue beat(8)4
Avg Revenue beat(8)13.91%
Revenue beat(12)5
Avg Revenue beat(12)3.45%
Revenue beat(16)7
Avg Revenue beat(16)-0.99%
PT rev (1m)10.89%
PT rev (3m)-51.46%
EPS NQ rev (1m)-20%
EPS NQ rev (3m)-40%
EPS NY rev (1m)-25.32%
EPS NY rev (3m)29.29%
Revenue NQ rev (1m)1.85%
Revenue NQ rev (3m)8.99%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.41 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.61 | ||
| P/tB | 14.26 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.49
EYN/A
EPS(NY)-1.93
Fwd EYN/A
FCF(TTM)-3.2
FCFYN/A
OCF(TTM)-2.69
OCFYN/A
SpS1.99
BVpS1.48
TBVpS0.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.04% | ||
| ROE | -54.76% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.91% | ||
| FCFM | N/A |
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
F-Score4
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.14 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.7 | ||
| Altman-Z | -6.88 |
F-Score4
WACC9.47%
ROIC/WACCN/A
Cap/Depr(3y)152.42%
Cap/Depr(5y)127.86%
Cap/Sales(3y)11.86%
Cap/Sales(5y)9.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.51%
EPS Next Y69.12%
EPS Next 2Y18.7%
EPS Next 3Y11.48%
EPS Next 5YN/A
Revenue 1Y (TTM)-28.23%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%10.18%
Revenue Next Year26.68%
Revenue Next 2Y35.26%
Revenue Next 3Y35.16%
Revenue Next 5Y64.44%
EBIT growth 1Y-13.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-11.89%
EBIT Next 3Y5.48%
EBIT Next 5YN/A
FCF growth 1Y43.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.22%
OCF growth 3YN/A
OCF growth 5YN/A
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP / FBIOP FAQ
Can you provide the ChartMill fundamental rating for FORTRESS BIOTECH INC - FBIO 9 3/8 PERP?
ChartMill assigns a fundamental rating of 2 / 10 to FBIOP.
What is the valuation status of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) stock?
ChartMill assigns a valuation rating of 0 / 10 to FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP). This can be considered as Overvalued.
What is the profitability of FBIOP stock?
FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) has a profitability rating of 2 / 10.
What is the expected EPS growth for FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) stock?
The Earnings per Share (EPS) of FORTRESS BIOTECH INC - FBIO 9 3/8 PERP (FBIOP) is expected to grow by 69.12% in the next year.